Physician profile
Scott A Smith
NPI 1972507853
$3,320.20
in general payments reported to CMS, 2019-2025
21 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $727 · 2021: $85.75 · 2023: $503 · 2024: $350 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948 · Travel and Lodging: $535 · Gift: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.89 |
| Travel and Lodging | $534.61 |
| Gift | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exactech, INC. | $863.26 | 2019-2023 | |
| Medinc of Texas | $617.21 | 2020 | |
| Arthrex, INC. | $534.61 | 2025 | |
| Stryker Corporation | $235.70 | 2024 | Aequalis Perform, System 9 Cd Nxt, 1788 |
| Kerecis Limited | $224.82 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Inari Medical, INC. | $158.73 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medical Device Business Services, INC. | $150.00 | 2023 | Va-Lcp |
| Osteocentric Technologies, INC. | $139.47 | 2019-2020 | |
| Linvatec Corporation | $97.07 | 2024 | Biobrace 23mm |
| Amgen INC. | $68.20 | 2019-2023 | Enbrel, Tavneos, Otezla |
| Zimmer Biomet Holdings, INC. | $47.50 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $29.27 | 2019-2020 | |
| Ucb, INC. | $23.87 | 2021 | |
| Ossur Americas, INC. | $20.00 | 2025 | |
| Radius Health, INC. | $19.50 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $17.36 | 2024 | Or3o Dual Mobility, Polarstem, Journey II |
| Janssen Biotech, INC. | $17.24 | 2023 | Simponi Aria |
| Davol INC. | $16.83 | 2021 | |
| Pfizer INC. | $15.47 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $12.69 | 2021 | |
| Celgene Corporation | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,001,885.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.